Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.72 |
| ▸ | EED | O75530 | 2/20 | 0.70 |
| ▸ | RBBP4 | Q09028 | 2/20 | 0.70 |
| ▸ | SUZ12 | Q15022 | 2/20 | 0.70 |
| ▸ | RBBP7 | Q16576 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10256635 | 0.87 | EZH2 (0.74) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL10256557 | 0.85 | EZH2 (0.72) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL10266369 | 0.85 | EZH2 (0.83) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL10257356 | 0.85 | EZH2 (0.74) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL12684020 | 0.85 | EZH2 (0.79) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL12684618 | 0.85 | EZH2 (0.79) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL19958882 | 0.85 | EZH2 (0.71) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL12684389 | 0.84 | EZH2 (0.81) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL10255294 | 0.84 | EZH2 (0.81) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL10257079 | 0.84 | EZH2 (0.70) | EZH2EEDRBBP4SUZ12RBBP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106659765-B | Use of dianhydrogalactitol and analogs or derivatives thereof for treating non-small cell lung cancer and ovarian cancer | 德玛医药 | 2021-08-13 | — | — | CN | disclosed |
| EP-3323820-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2018-05-23 | — | — | EP | disclosed |
| EP-3294284-A1 | COMBINATION OF ANALOGS OR DERIVATIVES OF DIANHYDROGALACTITOL WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT CANCER | Delmar Pharmaceuticals, Inc. (CA) | 2018-03-21 | — | — | EP | disclosed |
| EP-3125920-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | Del Mar Pharmaceuticals (CA) | 2017-02-08 | — | — | EP | disclosed |
| WO-2016183331-A1 | COMBINATION OF ANALOGS OR DERIVATIVES OF DIANHYDROGALACTITOL WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT CANCER | DELMAR PHARMACEUTICALS, INC. (CA) | 2016-11-17 | — | — | WO | disclosed |
| WO-2015154064-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2015-10-08 | — | — | WO | disclosed |
| EP-2681216-A2 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012118812-A2 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2012-09-07 | — | — | WO | disclosed |